Search research articles
Contact Us
Filters
Showing results (11-20 of 380) with videos related to
Page
of 38
Sort By:
The Lancet. Haematology
|
September 9, 2023
Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation
Anna Sureda, Eva Domingo-Domenech
Journal of Clinical Medicine
|
May 14, 2020
Treatment of Hodgkin Lymphoma Relapsed after Autologous Stem Cell Transplantation
Eva Domingo-Domènech, Anna Sureda
Cancer Treatment Reviews
|
October 31, 2003
High dose therapy and autologous stem cell transplant does not improve survival compared with continued combination chemotherapy in people at high risk of relapse after initial treatment of advanced Hodgkin's lymphoma
Donna E Reece, Anna Sureda
The Lancet. Haematology
|
October 7, 2018
Brentuximab vedotin for lymphoma in paediatric patients
Anna Sureda, Eva Domingo-Domènech
British Journal of Haematology
|
June 25, 2025
Allogeneic haematopoietic cell transplant should still be considered as a curative option for relapsed/refractory large B-cell lymphoma, including in the CAR T-cell era
Fernando Molina, Anna Sureda, Alberto Mussetti
Haematologica
|
September 25, 2025
Enhancing myeloablative fludarabine-busulfan conditioning with total marrow irradiation in high-risk myeloid disease
Fernando Molina, Alberto Mussetti, Anna Sureda
Hematology. American Society of Hematology. Education Program
|
December 9, 2023
CAR T-cell therapy in aggressive lymphomas-identifying prognostic and predictive markers
Alberto Mussetti, Nicole Fabbri, Anna Sureda
Seminars in Oncology
|
February 19, 2004
Allogeneic transplantation of hematopoietic stem cells after nonmyeloablative conditioning for Hodgkin's disease: indications and results
Norbert Schmitz, Anna Sureda, Stephen Robinson
The American Journal of Managed Care
|
January 21, 2026
It's time to reimagine reimbursement for CAR T-cell therapy
Anna Sureda, Meagan O'Neill, Brian O'Rourke
Cancers
|
December 10, 2021
Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy
Roser Velasco, Eva Domingo-Domenech, Anna Sureda
Page
of 38
Search research articles
Search
Showing results (11-20 of 380) with videos related to
Sort By:
Page
of 38
The Lancet. Haematology
|
September 9, 2023
Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation
Anna Sureda, Eva Domingo-Domenech
Journal of Clinical Medicine
|
May 14, 2020
Treatment of Hodgkin Lymphoma Relapsed after Autologous Stem Cell Transplantation
Eva Domingo-Domènech, Anna Sureda
Cancer Treatment Reviews
|
October 31, 2003
High dose therapy and autologous stem cell transplant does not improve survival compared with continued combination chemotherapy in people at high risk of relapse after initial treatment of advanced Hodgkin's lymphoma
Donna E Reece, Anna Sureda
The Lancet. Haematology
|
October 7, 2018
Brentuximab vedotin for lymphoma in paediatric patients
Anna Sureda, Eva Domingo-Domènech
British Journal of Haematology
|
June 25, 2025
Allogeneic haematopoietic cell transplant should still be considered as a curative option for relapsed/refractory large B-cell lymphoma, including in the CAR T-cell era
Fernando Molina, Anna Sureda, Alberto Mussetti
Haematologica
|
September 25, 2025
Enhancing myeloablative fludarabine-busulfan conditioning with total marrow irradiation in high-risk myeloid disease
Fernando Molina, Alberto Mussetti, Anna Sureda
Hematology. American Society of Hematology. Education Program
|
December 9, 2023
CAR T-cell therapy in aggressive lymphomas-identifying prognostic and predictive markers
Alberto Mussetti, Nicole Fabbri, Anna Sureda
Seminars in Oncology
|
February 19, 2004
Allogeneic transplantation of hematopoietic stem cells after nonmyeloablative conditioning for Hodgkin's disease: indications and results
Norbert Schmitz, Anna Sureda, Stephen Robinson
The American Journal of Managed Care
|
January 21, 2026
It's time to reimagine reimbursement for CAR T-cell therapy
Anna Sureda, Meagan O'Neill, Brian O'Rourke
Cancers
|
December 10, 2021
Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy
Roser Velasco, Eva Domingo-Domenech, Anna Sureda
Page
of 38